IQVIA Holdings Inc (NYSE: IQV)’s stock price has gone rise by 2.58 in comparison to its previous close of 137.00, however, the company has experienced a -2.09% decrease in its stock price over the last five trading days. https://www.prnewswire.com reported 2025-05-27 that Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and AI Technologies REDDING, Calif., May 27, 2025 /PRNewswire/ — According to a new market research report titled ‘RWE Oncology Solutions Market by Component (Datasets, Consulting Services), Application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance), End User, and Geography – Global Forecast to 2035’, the RWE oncology solutions market is projected to reach $3.51 billion by 2035, up from an estimated $893 million in 2025, growing at a CAGR of 14.7% during the forecast period. The growth of this market is mainly driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies. For more comprehensive insights, download the FREE report sample: https://www.meticulousresearch.com/download-sample-report/cp_id=5276 Key Market Drivers and Trends The RWE oncology solutions market is witnessing strong growth, primarily driven by the shift towards patient-centric healthcare models and the adoption of cloud-based RWE platforms that are reshaping traditional evidence generation approaches. Integration of genomic and molecular data with real-time data collection and analysis is gaining momentum. Market expansion is further supported by the growing integration with precision medicine initiatives and the development of AI-powered analytics solutions, especially in developed markets with advanced healthcare infrastructure across pharmaceutical, regulatory, and healthcare provider domains. Latest trends in the RWE oncology solutions market include the development of comprehensive cancer datasets across the healthcare ecosystem and the industry’s increasing focus on evidence-driven cancer care solutions. The market is increasingly focusing on robust, integrated platforms that merge comprehensive oncology datasets with advanced analytics capabilities to meet the demands of the rapidly evolving healthcare landscape. Growth Opportunities The market presents substantial growth opportunities in expansion in emerging markets, which offers substantial opportunities for market players looking to reach new customer bases. Another major opportunity lies in the integration with precision medicine initiatives, which enhances the accessibility of personalized cancer care. Additionally, the development of AI-powered analytics solutions and partnerships between healthcare stakeholders are generating new revenue streams for solution providers as organizations increasingly seek evidence-based alternatives to traditional healthcare decision-making methods. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) – https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Market Challenges Despite significant growth potential, the overall RWE oncology solutions market faces challenges including data privacy and security concerns straining implementation budgets, particularly in cost-sensitive healthcare sectors. Limited interoperability between healthcare systems is creating integration barriers. Additionally, recent global disruptions have exposed vulnerabilities in data standardization processes, affecting data quality and completeness. Rapidly evolving regulatory compliance requirements across different regions are creating implementation concerns, and high implementation and maintenance costs, especially for comprehensive RWE platforms, are delaying adoption, limiting scalability in key healthcare markets. Segment Insights The global RWE oncology solutions market is segmented by component (Datasets [Disparate Datasets, Integrated Datasets], Consulting Services), application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance, Other Applications), end user (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). Market by Component The Datasets segment is expected to account for the largest share of the overall RWE oncology solutions market in 2025, primarily driven by increasing demand for comprehensive cancer data across the healthcare ecosystem, including disparate datasets (EMR/EHR/clinical data, claims & billing data, pharmacy data, cancer registries) and integrated datasets. Their comprehensive coverage, data reliability, and broad adoption across diverse healthcare applications make them indispensable in pharmaceutical research, regulatory submissions, and healthcare decision-making. However, the Consulting Services segment is expected to grow at the fastest rate through 2035, fueled by the growing need for expertise in RWE study design, regulatory guidance, and data interpretation services. Request a customized research analysis tailored to your specific requirements: https://www.meticulousresearch.com/request-customization/cp_id=5276 Market by End User The Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to account for the largest share of the global RWE oncology solutions market in 2025, primarily due to their substantial investment in oncology R&D, regulatory requirements for post-market surveillance, and the essential requirement for real-world evidence capable of supporting drug development and regulatory submissions. However, the Healthcare Payers segment is expected to witness the highest growth rate during the forecast period, driven by increasing adoption of value-based care models, the need for cost-effectiveness evidence in coverage decisions, and increasing reliance on RWE for value-based healthcare decisions. Geographic Market Insights In 2025, North America is expected to hold the largest share of the global RWE oncology solutions market, followed by Europe, due to its advanced healthcare infrastructure, strong regulatory support for RWE, well-established pharmaceutical industry, favorable reimbursement policies, and the strong presence of prominent RWE solution providers. Additionally, high cancer incidence rates and mature data analytics capabilities contribute significantly to market dominance. However, the Asia-Pacific region, particularly China, India, and South Korea, is projected to experience the fastest growth during the forecast period. This acceleration is mainly driven by rising cancer burden, expanding healthcare infrastructure, growing pharmaceutical investments, increasing awareness about precision medicine approaches, and the region’s pivotal role as a global pharmaceutical manufacturing center. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/view-pricing/590 Competitive Landscape The global RWE oncology solutions market is characterized by a competitive and dynamic landscape, comprising established healthcare data analytics companies, pharmaceutical service providers, technology giants, and specialized oncology data solution providers, each adopting unique approaches to advancing RWE capabilities. Market evolution is increasingly shaped by trends such as data standardization, integration of disparate data sources, and the development of AI-powered analytics solutions designed to address regulatory compliance across different regions. Leading companies are leveraging advanced data analytics capabilities to achieve comprehensive evidence generation without compromising data quality and are incorporating enhanced security measures to meet the demands of sensitive healthcare data systems. Key players in the global RWE oncology solutions market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc., among others. Related Reports: Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User – Global Forecast to 2031https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954 Real-world Data (RWD) Market by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post Market Surveillance], End User (Pharma, Payers, Providers) – Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-data-market-5297 Real-world Evidence Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) – Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-evidence-analytics-market-5306 About Meticulous Research® We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. Each year, we conduct over 300 syndicated studies and manage 60+ consulting engagements across eight major sectors and 20+ geographic markets, all to deliver targeted business insights that help our clients lead in a rapidly evolving global market. With a strong focus on problem-solving for complex business challenges, our research enables organizations to navigate change with assertion, aligning it with strategic pathways for sustainable growth. By identifying innovative and effective solutions, we empower leaders to make impactful decisions that drive operational excellence and fuel innovation. We are committed to crafting insights that enhance business performance and help our clients unlock new revenue opportunities, positioning them for long-term success in the competitive global marketplace. To find out more, visit www.meticulousresearch.com or follow us on LinkedIn. Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected]Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Logo: https://mma.prnewswire.com/media/1757980/5251440/Meticulous_Research_Logo_1.jpg
Is It Worth Investing in IQVIA Holdings Inc (NYSE: IQV) Right Now?
IQVIA Holdings Inc (NYSE: IQV) has a price-to-earnings ratio of 19.15x that is above its average ratio. Additionally, the 36-month beta value for IQV is 1.31. There are mixed opinions on the stock, with 15 analysts rating it as a “buy,” 3 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for IQV is 171.50M and currently, short sellers hold a 1.64% ratio of that float. The average trading volume of IQV on May 28, 2025 was 2.13M shares.
IQV’s Market Performance
IQV stock saw a decrease of -2.09% in the past week, with a monthly decline of -6.48% and a quarterly a decrease of -26.41%. The volatility ratio for the week is 3.39%, and the volatility levels for the last 30 days are 3.03% for IQVIA Holdings Inc (IQV). . The simple moving average for the past 20 days is -4.41% for IQV’s stock, with a -29.57% simple moving average for the past 200 days.
Analysts’ Opinion of IQV
Many brokerage firms have already submitted their reports for IQV stocks, with HSBC Securities repeating the rating for IQV by listing it as a “Hold.” The predicted price for IQV in the upcoming period, according to HSBC Securities is $160 based on the research report published on April 25, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see IQV reach a price target of $170. The rating they have provided for IQV stocks is “Equal Weight” according to the report published on April 10th, 2025.
IQV Trading at -10.35% from the 50-Day Moving Average
After a stumble in the market that brought IQV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.42% of loss for the given period.
Volatility was left at 3.03%, however, over the last 30 days, the volatility rate increased by 3.39%, as shares sank -6.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.11% lower at present.
During the last 5 trading sessions, IQV fell by -2.09%, which changed the moving average for the period of 200-days by -38.79% in comparison to the 20-day moving average, which settled at $147.02. In addition, IQVIA Holdings Inc saw -28.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IQV starting from DANHAKL JOHN G, who purchase 1,275 shares at the price of $200.58 back on Dec 03 ’24. After this action, DANHAKL JOHN G now owns 1,275 shares of IQVIA Holdings Inc, valued at $255,740 using the latest closing price.
Sherbet Eric, the See Remarks of IQVIA Holdings Inc, sale 1,300 shares at $246.33 during a trade that took place back on Aug 27 ’24, which means that Sherbet Eric is holding 19,536 shares at $320,229 based on the most recent closing price.
Stock Fundamentals for IQV
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.35 for the gross margin
The net margin for IQVIA Holdings Inc stands at 0.09. The total capital return value is set at 0.11. Equity return is now at value 21.65, with 4.95 for asset returns.
Based on IQVIA Holdings Inc (IQV), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 2.43. The interest coverage ratio of the stock is 3.21.
Currently, EBITDA for the company is 3.49 billion with net debt to EBITDA at 3.76. When we switch over and look at the enterprise to sales, we see a ratio of 2.39. The receivables turnover for the company is 4.68for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
In conclusion, IQVIA Holdings Inc (IQV) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
